Pliant Therapeutics (PLRX) Set to Release Quarterly Earnings on Thursday

Key Points

• Pliant Therapeutics is expected to report third-quarter 2026 results before the market opens Thursday, November 5, with analysts forecasting a loss of $0.37 per share. The earnings call is scheduled for November 6 at 4:00 p.m. ET.
• The company reported a $0.36-per-share loss in the prior quarter, missing estimates by $0.02; analysts expect full-year and next-year losses of $1.42 and $1.53 per share, respectively.
• PLRX recently traded near $0.89, well below its 50-day and 200-day averages, while analyst sentiment remains mixed with a consensus Hold rating and a $3.00 average price target.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.37) per share for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). On average, analysts expect Pliant Therapeutics to post ($1.42) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Pliant Therapeutics Trading Up 3.8%

PLRX opened at $0.89 on Thursday. The stock has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.17. The company has a market cap of $55.10 million, a price-to-earnings ratio of -0.60 and a beta of 1.27. Pliant Therapeutics has a 12-month low of $0.83 and a 12-month high of $1.81.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen raised Pliant Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 26th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Pliant Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company's research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver.

Pliant's lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.